期刊文献+

Interleukin-18 Suppresses Angiogenesis and Lymphangiogenesis in Implanted Lewis Lung Cancer 被引量:1

Interleukin-18 Suppresses Angiogenesis and Lymphangiogenesis in Implanted Lewis Lung Cancer
下载PDF
导出
摘要 Objective: To investigate the effects of interleukin-18 (IL-18) on implanted Lewis lung cancer in suppressing angiogenesis and lymphangiogenesis. Methods: One week after hypodermic inoculation of Lewis cells, sixteen tumor-bearing syngeneic mice were randomly divided into two groups. The mice in the treatment group (group A) were intraperitoneally injected with the IL-18 and in the control group (group B) were intraperitoneally injected with normal saline for 7 days. The mice were killed on day 19. The morphology of the tumors was studied, the growth curve was described and the tumor inhibition rate was calculated. The numbers of metastasized pulmonary colonies were calculated using hematoxylin-eosin (HE) staining. The vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor C (VEGF-C), microvessel density (MVD) and lymphatic microvessel density (LMVD) in tumor mass were measured by immunohistochemistry staining (IHCS). Results: In the group A, the tumor volume, tumor weigh, lung metastatic nodules, expression of VEGF-A and VEGF-C, MVD were all decreased significantly (P0.01 or P0.05). The tumor inhibition rate was 75% and the inhibition rate of lung metastatic nodules was 61%. The LMVD in group A was also lower than group B, but without significant difference (P0.05). Conclusion: IL-18 could suppress the tumor growth and metastasis of implanted Lewis lung cancer by way of down-regulating VEGF-A and VEGF-C expression, suppressing angiogenesis and lymphangiogenesis. Objective: To investigate the effects of interleukin-18 (IL-18) on implanted Lewis lung cancer in suppressing angiogenesis and lymphangiogenesis. Methods: One week after hypodermic inoculation of Lewis cells, sixteen tumor-bearing syngeneic mice were randomly divided into two groups. The mice in the treatment group (group A) were intraperitoneally injected with the IL-18 and in the control group (group B) were intraperitoneally injected with normal saline for 7 days. The mice were killed on day 19. The morphology of the tumors was studied, the growth curve was described and the tumor inhibition rate was calculated. The numbers of metastasized pulmonary colonies were calculated using hematoxylin-eosin (HE) staining. The vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor C (VEGF-C), microvessel density (MVD) and lymphatic microvessel density (LMVD) in tumor mass were measured by immunohistochemistry staining (IHCS). Results: In the group A, the tumor volume, tumor weigh, lung metastatic nodules, expression of VEGF-A and VEGF-C, MVD were all decreased significantly (P0.01 or P0.05). The tumor inhibition rate was 75% and the inhibition rate of lung metastatic nodules was 61%. The LMVD in group A was also lower than group B, but without significant difference (P0.05). Conclusion: IL-18 could suppress the tumor growth and metastasis of implanted Lewis lung cancer by way of down-regulating VEGF-A and VEGF-C expression, suppressing angiogenesis and lymphangiogenesis.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2010年第4期303-309,共7页 中国癌症研究(英文版)
基金 supported by the Natural Science Foundation of Fujian Province (No. 2006J0342) Scholastic Development Foundation of Fujian Medical University (No. JS07006)
关键词 INTERLEUKIN-18 Lung cancer VEGF LMVD Interleukin-18 Lung cancer VEGF LMVD
  • 相关文献

参考文献4

二级参考文献13

  • 1Malaya GUPTA,Upal Kanti MAZUMDER,Ramanathan Sambath KUMAR,Thangavel Siva KUMAR.Antitumor activity and antioxident role of Bauhinia racemosa against Ehrlich ascites carcinoma in Swiss albino mice[J].Acta Pharmacologica Sinica,2004,25(8):1070-1076. 被引量:7
  • 2Joukov V, Pajusola K, KaiPainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 ( VEGFR-3 ) and KDR ( VEGFR-2 ) receptor tyrosine kinases. EMBO J, 1996, 15: 290-298.
  • 3Tanaka K, Kurebayashi J, Sonoo H, et al. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg Today, 2002, 32: 761-768.
  • 4Fromowitz FB, Viola MV, Chao S, et al. ras p21 expression in the progression of breast cancer. Hum Pathol, 1987, 18: 1268- 1275.
  • 5Takizawa H, Kondo K, Fujino H, et al. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br J Cancer, 2006, 95 : 75-79.
  • 6Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer, 2005, 104: 1668-1677.
  • 7Saintigny P, Kambouchner M, Ly M, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer, 2007, 58: 205-213.
  • 8Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in nonsmall cell lung cancer patients. Br J Cancer, 2004, 91 : 498-503.
  • 9Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2- mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer, 2006, 94 : 1154-1163.
  • 10Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol, 1997, 188 : 96-109.

共引文献40

同被引文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部